English
Back
Download
Log in to access Online Inquiry
Back to the Top

$Sensei Biotherapeutics (SNSE.US)$ NEWS Sensei Biotherapeuti...

NEWS
Sensei Biotherapeutics, Inc. (SNSE) announces the publication of a research paper in Nature Communications detailing the development of SNS-101, a pH-sensitive monoclonal antibody targeting VISTA to suppress T-cell activation in cancer patients. The paper highlights the unique mechanism of SNS-101 in mitigating CRS risk and maintaining a favorable safety profile, potentially revolutionizing VISTA-directed immunotherapy.
Disclaimer: Community is offered by Moomoo Technologies Inc. and is for educational purposes only. Read more
Translate
Report
13K Views
Comment
Sign in to post a comment
    Spread kindness and love. Life is short. Don’t let greed eat you.
    9568
    Followers
    55
    Following
    116K
    Visitors
    Follow

    Market Insights

    Market Hot Picks Market Hot Picks
    Unlock Now